Finanzen von Scribe Therapeutics Inc. Common Stock (SCTX)SCTXScribe Therapeutics Inc. Common Stock

Evaluating the bottom line, Scribe Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -489.83%, while the net margin is -337.70%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SCTX converts its operational activities into shareholder value.

In the context of the broader market, SCTX competes directly with industry leaders such as SABS and BNTC. With a market capitalization of $317.65M, it holds a significant position in the sector. When comparing efficiency, SCTX's gross margin of 100.00% stands against SABS's N/A and BNTC's N/A. Such benchmarking helps identify whether Scribe Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Scribe Therapeutics has shown a gross margin of 100% across recent quarters, but it has also reported substantial net losses, including -17.35 million in Q1 2026 and -6.48 million in Q2 2026. This indicates that while the company is generating revenue, it is struggling to convert that into profit.